Nippon India Pharma Fund – Direct Growth

Equity · Sectoral / Thematic
 · ★★★★
100
Min SIP
5,000
Min Lumpsum
0.97 %
Expense Ratio
★★★★
Rating
6,891
Fund Size (in Cr)
11 Years
Fund Age
Mutual Fund SIP Calculator
Monthly Investment
Max: ₹1,00,000
Investment Period
Yrs
Max: 5 yrs
  • Invested Amount
    --
  • Wealth Gained
    --
  • Expected Amount
    --

Scheme Performance

Returns and Ranks ( as on 01 March 2024 )
1Y1Y 3Y3Y 5Y5Y MaxMax
Trailing Returns 62.5% 22.1% 24.7% 18.7%
Category Average 61.1% 18.7% 21% -

Scheme Allocation

By Holding
By Sector
By Asset
8.31%
6.08%
Others
61.24%
View all Holdings
Holdings Sector Instrument Asset
Sun Pharma.Inds. Pharmaceuticals Equity 13.5%
Lupin Pharmaceuticals Equity 8.31%
Cipla Pharmaceuticals Equity 6.08%
Apollo Hospitals Healthcare Equity 5.98%
Dr Reddy's Labs Pharmaceuticals Equity 4.89%
Gland Pharma Pharmaceuticals Equity 4.83%
Divi's Lab. Pharmaceuticals Equity 4.53%
Aurobindo Pharma Pharmaceuticals Equity 3.84%
J B Chem & Pharm Pharmaceuticals Equity 3.63%
Narayana Hrudaya Healthcare Equity 3.34%
Zydus Lifesci. Pharmaceuticals Equity 3.31%
Medplus Health Retail Equity 3.2%
Ajanta Pharma Pharmaceuticals Equity 3.05%
Vijaya Diagnost. Healthcare Equity 3.03%
Sanofi India Pharmaceuticals Equity 2.97%
Abbott India Pharmaceuticals Equity 2.87%
Glaxosmi. Pharma Pharmaceuticals Equity 2.79%
Alkem Lab Pharmaceuticals Equity 2.74%
Mankind Pharma Pharmaceuticals Equity 2.61%
Torrent Pharma. Pharmaceuticals Equity 2.22%
Fortis Health. Healthcare Equity 2.19%
Pfizer Pharmaceuticals Equity 2%
Thyrocare Tech. Healthcare Equity 1.56%
Syngene Intl. Pharmaceuticals Equity 1.22%
Concord Biotech Pharmaceuticals Equity 1.06%
Orchid Pharma Pharmaceuticals Equity 1.05%
Indoco Remedies Pharmaceuticals Equity 0.99%
Metropolis Healt Healthcare Equity 0.49%
Jubilant Pharmo Pharmaceuticals Equity 0.46%
Health.Global Healthcare Equity 0.22%
Tarsons Products Miscellaneous Equity 0.16%
Astrazeneca Phar Pharmaceuticals Equity 0.11%
Pharmaceuticals & Biotech
77.84%
Healthcare Services
18.03%
Retailing
3.2%
Debt
0.96%
Healthcare Equipment & Su
0.16%
Equity
99.23%
Reverse Repos
0.96%
Cash & Cash Equivalents
0.01%
Net Curr Ass/Net Receivables
-0.2%

Advance Ratio

2.12
Alpha
4.48
SD
0.96
Beta
0.85
Sharpe

Exit Load

Exit Load 1% if redeemed or switchd out on or efore completion of 1 Months from the date of allotment of units. NIl if redeemed or switched out after the completion of 1 Months from the date of allotment of units.

Fund Objective

The Nippon India Pharma Fund is an equity scheme investing in the pharma sector. It was launched on 5th June 2004 by Nippon India Mutual Fund.

The Nippon India Pharma Fund distributes its investments across pharmaceuticals and biotechnology, and healthcare services companies of the pharma sector. It is managed by Sailesh Raj Bhan.

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity-related or fixed-income securities of companies in the pharmaceutical and related industries. It aims to achieve its objective by investing in companies that meet criteria such as strong management, established performance history, growth potential, and favourable industry economic conditions.

The Nippon India Pharma Fund invests at least 80% of its assets in equity and related instruments. It has the flexibility to invest up to 20% of its assets in debt, money market instruments, REITs, and InvITs.

Pros & Cons

Pros

Cons

Since its inception, the Nippon India Pharma Fund’s annualised returns have consistently beaten its category average and benchmark, the S&P BSE Healthcare TRI. The Nippon India Pharma Fund has a higher beta and standard deviation than its category average, indicating volatility.
It has delivered higher alpha in the past three years than its benchmark and category average, indicating superior performance. As a sector-specific scheme, it limits its investment universe to companies in the pharmaceutical sector, potentially reducing the opportunity for diversification and increasing the risk of an over-concentrated portfolio.
The scheme has demonstrated a better Sharpe ratio than the category average in the last three years, showcasing its ability to generate higher returns per unit of risk. The scheme is tailored for long-term investments, with its strategy and growth prospects aligned for a multi-year time horizon. Therefore, investors must be willing to hold the scheme for an extended period.

 

How to invest in Nippon India Pharma Fund?

5paisa makes it simple and convenient for users to invest in the Nippon India Pharma Fund Direct-Growth. The procedure is straightforward, can be finished quickly, and does not include any paperwork at any point. Invest a few minutes in carrying out the steps listed below:

Step 1: Log in to your 5Paisa Account. If you do not have one, register and create a new 5Paisa account in 3 easy steps. Alternatively, you can download the 5Paisa app on your smartphone for Android or IOS and log in from your device.
Step 2: Search for the Nippon India Mutual Fund scheme that you want to invest in
Step 3: Select the option that is apt for your requirement and risk appetite
Step 4: Select the investment type – SIP (Systematic Investment Plan) or Lumpsum
Step 5: Input the amount that you’d like to invest and proceed with payment by clicking on the ‘Invest Now’ button

That’s it! This sums up the investment process. Once your payment is successful, you can see the Nippon India Mutual Fund reflected in your 5Paisa account in 3-4 working days. If you have selected the SIP option, the chosen amount will get deducted every month starting from the date you have made the payment.

What is the expense ratio of the Nippon India Pharma Fund?

When referring to the Nippon India Pharma Fund Direct-Growth or any other mutual fund, the word “Expense Ratio” refers to the fund’s annual operating expenses as a percentage of its total assets, which can impact a scheme’s returns for investors. A lower expense ratio usually means the fund is less costly and may generate higher returns for the investors.

Who should invest in Nippon India Pharma Fund?

The Nippon India Pharma Fund is ideal for investors seeking long-term capital appreciation and investment in equity and equity-related securities of pharma and related companies. Investors looking to include a focused pharma sector investment in their overall asset allocation strategy should consider this scheme.

The scheme has exceeded the performance of the S&P BSE Healthcare TRI since its inception, with a compound annual growth rate (CAGR) of around 15.4% over the same period, highlighting its annualised growth performance.

The Nippon India Pharma Fund is ideal for those with a long-term investment strategy and a willingness to accept very high levels of risk. It is suitable for investors who have a keen understanding of macro trends and are looking for high-return investments. This fund is not recommended for those who prefer short-term or risk-averse options. Investors should be prepared to hold the scheme for a minimum of 2 to 3 years and must understand that there may be losses even in favourable market conditions.

What are the benefits of investing in the Nippon India Pharma Fund?

● The Nippon India Pharma Fund offers the advantage of having a concentrated portfolio of pharmaceutical companies, increasing the potential for generating alpha and achieving long-term wealth creation.
● The scheme has consistently outperformed its benchmark and category average since its inception, delivering a CAGR of around 15.4%.
● It invests in the pharmaceutical sector, characterised by low capital requirements and strong cash flows, thereby reducing the impact of overall market fluctuations.
● The pharma and healthcare segment is poised for multiple years of steady growth, driven by factors such as increasing domestic demand, boosted exports, stabilising US markets, growth in healthcare services, and insurance penetration.
● The Nippon India Pharma Fund offers a comprehensive investment opportunity, with holdings across key pharmaceutical industry segments, including domestic and international companies, branded and generic drugs, and contract research and manufacturing.
● It adopts a structured approach to managing investment risk, including ongoing market and economic analysis, research investments, and bonds and debentures assigned investment grade ratings by approved rating agencies.

Fund Managers

Sailesh Raj Bhan

Risk-O-Meter

Peer Comparison

Fund Name

AMC Contact Details

Nippon India Mutual Fund
AUM:
3,80,049 Cr
Address:
4th Floor, Tower A, Peninsula Busines -s Park, Ganapatrao Kadam Marg Lower Parel (W), Mumbai - 400013.
Contact:
022-68087000/1860260111
Email ID:
customercare@nipponindiaim.in

More Funds from Nippon India Mutual Fund

Fund Name

Mutual Funds By Category

Equity

Debt

Hybrid

equity
Large Cap Mutual Funds Large Cap Mutual Funds
Large Cap
Fund Name
Mid Cap Mutual Funds Mid Cap Mutual Funds
Mid Cap
Fund Name
Small Cap Mutual Funds Small Cap Mutual Funds
Small Cap
Fund Name
Multi Cap Funds Multi Cap Funds
Multi Cap
Fund Name
ELSS Mutual Funds ELSS Mutual Funds
ELSS
Fund Name
Dividend Yield Funds Dividend Yield Funds
Dividend Yield
Fund Name
Sectoral / Thematic Mutual Funds Sectoral / Thematic Mutual Funds
Sectoral / Thematic
Fund Name
Focused Funds Focused Funds
Focused
Fund Name
debt
Ultra Short Duration Funds Ultra Short Duration Funds
Ultra Short Duration
Fund Name
Liquid Mutual Funds Liquid Mutual Funds
Liquid
Fund Name
Gilt Mutual Funds Gilt Mutual Funds
Gilt
Fund Name
Long Duration Funds Long Duration Funds
Long Duration
Fund Name
Overnight Mutual Funds Overnight Mutual Funds
Overnight
Fund Name
Floater Mutual Funds Floater Mutual Funds
Floater
Fund Name
hybrid
Arbitrage Mutual Funds Arbitrage Mutual Funds
Arbitrage
Fund Name
Equity Savings Mutual Funds Equity Savings Mutual Funds
Equity Savings
Fund Name
Aggressive Hybrid Mutual Funds Aggressive Hybrid Mutual Funds
Aggressive Hybrid
Fund Name

Frequently Asked Questions

How to invest in Nippon India Pharma Fund – Direct Growth ?

You can invest in Nippon India Pharma Fund – Direct Growth in a quick and simple process. Follow the below steps;
  • Login to your 5paisa account, Go to the Mutual Funds section.
  • Search for Nippon India Pharma Fund – Direct Growth in the search box.
  • Click on "Start SIP" if you wish to do a SIP or click on “One-time” if you wish to invest a lumpsum amount then click on "Invest Now"

What is the NAV of Nippon India Pharma Fund – Direct Growth ?

The NAV of Nippon India Pharma Fund – Direct Growth is ₹468.8 as of 01 March 2024.

How to redeem Nippon India Pharma Fund – Direct Growth holding ?

You can go to your holding on the app and click on the fund name you will get two options Invest More and Redeem; click on redeem and enter the amount or units you desire to redeem or you can tick on “Redeem all units”.

What is the minimum sip amount of Nippon India Pharma Fund – Direct Growth?

The minimum SIP amount of Nippon India Pharma Fund – Direct Growth is ₹100

What are the top sectors Nippon India Pharma Fund – Direct Growth has invested in?

The top sectors Nippon India Pharma Fund – Direct Growth has invested in are
  1. Pharmaceuticals & Biotech - 77.84%
  2. Healthcare Services - 18.03%
  3. Retailing - 3.2%
  4. Debt - 0.96%
  5. Healthcare Equipment & Su - 0.16%

Can I make investments in both the SIP and Lump Sum schemes of Nippon India Pharma Fund – Direct Growth?

Yes, You can select both SIP or Lumpsum investment of Nippon India Pharma Fund – Direct Growth based on your investment objective and risk tolerance.

How much returns have Nippon India Pharma Fund – Direct Growth generated ?

The Nippon India Pharma Fund – Direct Growth has delivered 18.7% since inception

What is the expense ratio of Nippon India Pharma Fund – Direct Growth ?

The expense ratio of Nippon India Pharma Fund – Direct Growth is 0.97 % as of 01 March 2024.

What is the AUM of Nippon India Pharma Fund – Direct Growth?

The AUM of Nippon India Pharma Fund – Direct Growth is ₹3,80,049 Cr as of 01 March 2024

What are the top stock holdings of Nippon India Pharma Fund – Direct Growth?

The top stock holdings of Nippon India Pharma Fund – Direct Growth are
  1. Sun Pharma.Inds. - 13.5%
  2. Lupin - 8.31%
  3. Cipla - 6.08%
  4. Apollo Hospitals - 5.98%
  5. Dr Reddy's Labs - 4.89%

How can I redeem my investments in Nippon India Pharma Fund – Direct Growth?

Step 1: Visit the fund house's website
Step 2: Log in to your account by adding Folio No. and M-Pin
Step 3: Click on Widhrawal > Redemption
Step 4: Select Nippon India Pharma Fund – Direct Growth in Scheme, enter the redemption amount, and click on submit button.
Invest Now